While enhanced expression of CLDN4 in luminal breast cancers was linked to poor clinical outcomes, contrastingly, overexpression of CLDN4 in TNBC was associated with favorable outcomes in which tumors that overexpressed CLDN4 displayed a less aggressive phenotype [53]. The gene discussed is CLDN4; the disease is breast carcinoma.